Found 946 clinical trials
Biofilm Epidemiology and Mechanisms in Colon Cancer
Biofilm Epidemiology and Mechanisms in Colon Cancer
- 128 views
- 23 Nov, 2020
- 1 location
What if there were a simpler way to find colorectal cancer?
ECLIPSE is being done to find out if a simple blood test can find early signs of colorectal cancer. Colorectal cancer is the #2 cause of death among adults with cancer, but it doesn’t have to be. If found early, it’s one of the most preventable and treatable cancers. NOW …
- 13 views
- 23 Nov, 2020
- 1 location
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
A study to evaluate a blood test to detect colorectal cancer in patients going for screening colonoscopies.
- 19 views
- 17 May, 2021
- 1 location
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (KRYSTAL-10)
Study 849-010 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.
- 0 views
- 18 May, 2021
- 13 locations
A Phase 1/2 Trial of MRTX849 in Combination with TNO155 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
Characterize the safety and tolerability, and evaluate Pharmacokinetics of MRTX849 in combination with TNO155 in patients with advanced solid tumor malignancies with KRAS G12C mutation. MRTX849 is an orally available small molecute inhibitor of KRASG12C. TNO155 is a selective, orally bioavailable allosteric inhibitor of wild type SHP2.
- 114 views
- 19 Feb, 2021
- 10 locations
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation
Evaluates the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally-available small molecule inhibitor of KRAS G12C.
- 405 views
- 08 Mar, 2021
- 67 locations
CALGB 80702: A Phase III trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer.
CALGB 80702: A Phase III trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer.
- 124 views
- 08 Nov, 2020
- 1 location
A Study Evaluating the Safety and Efficacy of Remimazolam (CNS 7056) Compared to Placebo and Midazolam in ASA III and IV Patients Undergoing Colonoscopy
A Study Evaluating the Safety and Efficacy of Remimazolam (CNS 7056) Compared to Placebo and Midazolam in ASA III and IV Patients Undergoing Colonoscopy
- 178 views
- 08 Nov, 2020
- 1 location
Triple IN Study (Inhibition of Incisional Infections): Phase 3 Study of Efficacy and Safety of Topical E-101 Solution to Prevent Incisional Infections among Colorectal Surgery Patients
Triple IN Study (Inhibition of Incisional Infections): Phase 3 Study of Efficacy and Safety of Topical E-101 Solution to Prevent Incisional Infections among Colorectal Surgery Patients
- 110 views
- 08 Nov, 2020
- 1 location
Rural Colon Cancer Screening Toolkit Intervention
Less than half of all positive fecal immunochemical testing (FIT)s are followed-up by colonoscopy, thus limiting the full potential of colorectal cancer (CRC) screening to reduce mortality. Given the need for coordination in order to achieve high rates of follow-up, multilevel approaches are needed. Such approaches could be particularly beneficial …
- 0 views
- 27 Jan, 2021
- 1 location